{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:49:08Z","timestamp":1784306948887,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>The findings from this study using monotherapy with pemetrexed in a pretreated patient population are, overall, encouraging. Unlike high-dose methotrexate, which requires several days of inpatient hospitalization, pemetrexed is relatively easy to administer in the outpatient setting and remains a viable treatment option in this patient population. The maximum tolerated dose of pemetrexed administered (900 mg\/m2 every 2\u2009weeks) was generally well tolerated and showed activity in patients with relapsed or refractory CNSL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is currently no standard salvage treatment for patients with relapsed\/refractory central nervous system (CNS) lymphoma (CNSL). We report the results of a phase I study of pemetrexed, an antifolate drug with broader activity than methotrexate (MTX). We provide the safety, tolerability, and maximum tolerated dose (MTD) of pemetrexed in patients with recurrent CNSL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Through October 2015, 17 patients with relapsed\/refractory CNSL received pemetrexed every 2\u2009weeks with the first cohort receiving 600 mg\/m2 and dose escalation in increments of 300 mg\/m2 to a maximum of 1,200 mg\/m2. Three patients were to enroll at each dose level with expansion to six patients in the event of dose-limiting toxicity. Patients with both primary CNS lymphoma (PCNSL) and secondary CNS lymphoma (SCNSL) could be enrolled.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventeen patients were evaluable with a median age of 63.7\u2009years. Main adverse events included fatigue (82.4%), anemia (82.4%), and neutropenia (70.6%). The MTD was established at 900 mg\/m2. Dose-limiting toxicities were recorded in one patient in the 600 mg\/m2 cohort and in two patients in the 1,200 mg\/m2 cohort. Fourteen patients were evaluable for response assessment; 21.4% achieved a complete response, 35.7% had a partial response, 14.3% had stable disease, and 28.6% had progressive disease. The median progression-free survival was 4.2 months. The median overall survival was 44.5 months.<\/jats:p>\n                  <jats:p>In the original study protocol, the plan was to add an expansion cohort of six patients at MTD level. However, the first phase of the study was characterized by slow recruitment. Therefore, after achieving the primary objective of the study and establishing the MTD, the investigators decided to amend the protocol and to close the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Pemetrexed administered at 900 mg\/m2 every 2\u2009weeks exhibits single-agent activity in patients with recurrent CNSL; it is well tolerated, and side effects are manageable.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2020-0489","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T12:39:49Z","timestamp":1591792789000},"page":"747-e1273","source":"Crossref","is-referenced-by-count":13,"title":["Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial"],"prefix":"10.1093","volume":"25","author":[{"given":"Jorg","family":"Dietrich","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Versmee","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Drappatz","sequence":"additional","affiliation":[{"name":"University of Pittsburg School of Medicine, Pittsburgh, Pennsylvania, USA"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April F.","family":"Eichler","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nayak","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Norden","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wong","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Pisapia","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SooAe S.","family":"Jones","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda B.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Chabner","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Hochberg","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy T.","family":"Batchelor","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"2021122510523932300_onco13401-bib-0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11060-013-1196-1","article-title":"Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma","volume":"115","author":"Zhang","year":"2013","journal-title":"J Neurooncol"},{"key":"2021122510523932300_onco13401-bib-0002","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1002\/cncr.26709","article-title":"Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma","volume":"18","author":"Raizer","year":"2012","journal-title":"Cancer"},{"key":"2021122510523932300_onco13401-bib-0003","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12094-015-1345-4","article-title":"Pemetrexed for primary central nervous system lymphoma in the elderly","volume":"18","author":"Han","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"2021122510523932300_onco13401-bib-0004","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-014-0351-7","article-title":"Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma","volume":"32","author":"Zhao","year":"2015","journal-title":"Med Oncol"},{"key":"2021122510523932300_onco13401-bib-0005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1124\/jpet.105.090043","article-title":"Distribution of the novel antifolate pemetrexed to the brain","volume":"315","author":"Dai","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122510523932300_onco13401-bib-0006","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00280-006-0285-7","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates","volume":"59","author":"Stapleton","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122510523932300_onco13401-bib-0007","doi-asserted-by":"crossref","first-page":"599","DOI":"10.21037\/tlcr.2016.11.01","article-title":"State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer","volume":"5","author":"Inno","year":"2016","journal-title":"Trans Lung Cancer Res"},{"key":"2021122510523932300_onco13401-bib-0008","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","article-title":"Phase I and pharmacokinetic study of pemetrexed administered every 3\u2009weeks to advanced cancer patients with normal and impaired renal function","volume":"24","author":"Mita","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122510523932300_onco13401-bib-0009","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1053\/j.ajkd.2011.04.030","article-title":"Kidney tubular toxicity of maintenance pemetrexed therapy","volume":"58","author":"Glezerman","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2021122510523932300_onco13401-bib-0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00884-2018","article-title":"Renal impairment during pemetrexed maintenance in patients with advanced non small cell lung cancer: A cohort study","volume":"52","author":"Visser","year":"2018","journal-title":"Eur Respir J"},{"key":"2021122510523932300_onco13401-bib-0011","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","article-title":"Treatment of relapsed central nervous system lymphoma with high-dose methotrexate","volume":"10","author":"Plotkin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122510523932300_onco13401-bib-0012","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jocn.2012.04.001","article-title":"A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide","volume":"19","author":"Wong","year":"2004","journal-title":"J Clin Neurosci"},{"key":"2021122510523932300_onco13401-bib-0013","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6603660","article-title":"Temozolomide as salvage treatment in primary brain lymphomas","volume":"96","author":"Reni","year":"2007","journal-title":"Br J Cancer"},{"key":"2021122510523932300_onco13401-bib-0014","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1212\/01.WNL.0000137050.43114.42","article-title":"Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide","volume":"63","author":"Enting","year":"2004","journal-title":"Neurology"},{"key":"2021122510523932300_onco13401-bib-0015","first-page":"1501","article-title":"Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma","volume":"19","author":"Nayak","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2021122510523932300_onco13401-bib-0016","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"Bachelor","year":"2011","journal-title":"Neurology"},{"key":"2021122510523932300_onco13401-bib-0017","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.2037","article-title":"Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy","volume":"31","author":"Mappa","year":"2013","journal-title":"Hematol Oncol"},{"key":"2021122510523932300_onco13401-bib-0018","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdl070","article-title":"Prospective trial on topotecan salvage therapy in primary CNS lymphoma","volume":"17","author":"Fischer","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122510523932300_onco13401-bib-0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-007-9464-6","article-title":"Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma","volume":"86","author":"Voloshin","year":"2008","journal-title":"J Neurooncol"},{"key":"2021122510523932300_onco13401-bib-0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","author":"Houiller","year":"2015","journal-title":"Neurology"},{"key":"2021122510523932300_onco13401-bib-0021","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"key":"2021122510523932300_onco13401-bib-0022","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"2021122510523932300_onco13401-bib-0023","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdq548","article-title":"Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy","volume":"22","author":"Khimani","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122510523932300_onco13401-bib-0024","doi-asserted-by":"crossref","first-page":"2141a","DOI":"10.1200\/jco.2004.22.90140.2141","article-title":"A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors","volume":"22","author":"Dudek","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0489","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/9\/747\/41919722\/oncolo_25_9_747.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/9\/747\/41919722\/oncolo_25_9_747.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:53:13Z","timestamp":1640429593000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/9\/747\/6443860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,7,1]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0489","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2020,7,1]]}}}